Peritumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of resistance to immune control?

High expression of FOXP3 in primary melanoma is associated with tumour progression

(2013) A.L. Gerber et al.   BRITISH JOURNAL OF DERMATOLOGY

Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types

(2013) P. A. Ascierto et al.   CLINICAL CANCER RESEARCH

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

(2013) Rikke B. Holmgaard et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells

(2013) S. Spranger et al.   Science Translational Medicine

Host Indoleamine 2,3-Dioxygenase: Contribution to Systemic Acquired Tumor Tolerance

(2012) Theodore S. Johnson et al.   IMMUNOLOGICAL INVESTIGATIONS

Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer

(2011) L Ferdinande et al.   BRITISH JOURNAL OF CANCER

An immune-active tumor microenvironment favors clinical response to ipilimumab

(2011) Rui-Ru Ji et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Skin delivery of short hairpin RNA of indoleamine 2,3 dioxygenase induces antitumor immunity against orthotopic and metastatic liver cancer

(2011) Tzu-Ting Huang et al.   CANCER SCIENCE

IDO recruits Tregs in melanoma

(2011) George Prendergast et al.   CELL CYCLE

Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival

(2011) Jonathan R. Brody et al.   CELL CYCLE

Involvement of Indoleamine 2,3-Dioxygenase in Impairing Tumor-Infiltrating CD8+T-Cell Functions in Esophageal Squamous Cell Carcinoma

(2011) Ge Zhang et al.   Clinical & Developmental Immunology

Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients

(2011) Reinhart Speeckaert et al.   EUROPEAN JOURNAL OF CANCER

High expression of indoleamine 2,3-dioxygenase in the tumour is associated with medullary features and favourable outcome in basal-like breast carcinoma

(2011) Jocelyne Jacquemier et al.   INTERNATIONAL JOURNAL OF CANCER

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

(2011) Omid Hamid et al.   Journal of Translational Medicine

Molecular Profiling of Melanoma and the Evolution of Patient-Specific Therapy

(2011) Thomas F. Gajewski   SEMINARS IN ONCOLOGY

Hypoxia regulates the production and activity of glucose transporter-1 and indoleamine 2,3-dioxygenase in monocyte-derived endothelial-like cells: possible relevance to infantile haemangioma pathogenesis

(2010) A. Herbert et al.   BRITISH JOURNAL OF DERMATOLOGY

Inverse Correlation between Tumoral Indoleamine 2,3-Dioxygenase Expression and Tumor-Infiltrating Lymphocytes in Endometrial Cancer: Its Association with Disease Progression and Survival

(2008) K. Ino et al.   CLINICAL CANCER RESEARCH

High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome

(2008) M. E.D. Chamuleau et al.   HAEMATOLOGICA